急性呼吸窘迫综合征治疗的未来方向。
Future Directions in Therapies for Acute Respiratory Distress Syndrome.
机构信息
Baillie-Gifford Pandemic Science Hub, Centre for Inflammation Research, Institute for Repair and Regeneration, University of Edinburgh, The Roslin Institute, Easter Bush Campus, Midlothian, Edinburgh EH25 9RG, UK; Department of Critical Care, Queen Elizabeth University Hospital, Glasgow, UK.
Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, University Road, Belfast BT7 1NN, UK.
出版信息
Clin Chest Med. 2024 Dec;45(4):943-951. doi: 10.1016/j.ccm.2024.08.014. Epub 2024 Sep 20.
Acute respiratory distress syndrome (ARDS) is caused by a complex interplay among hyperinflammation, endothelial dysfunction, and alveolar epithelial injury. Targeted treatments toward the underlying pathways have been unsuccessful in unselected patient populations. The first reliable biological subphenotypes reflective of these biological disease states have been identified in the past decade. Subphenotype targeted intervention studies are needed to advance the pharmacologic treatment of ARDS.
急性呼吸窘迫综合征（ARDS）是由过度炎症、内皮功能障碍和肺泡上皮损伤之间的复杂相互作用引起的。针对潜在途径的靶向治疗在未选择的患者群体中并未取得成功。过去十年中已经确定了反映这些生物学疾病状态的第一个可靠的生物学亚表型。需要针对亚表型的干预研究来推进 ARDS 的药物治疗。
Zotero 插件